glp-1 drugs for obesity from the Gray Market GLP-1 receptor agonists – How
Description
A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D
Diabetes Research And Clinical Practice, 172 ,
Here, we review the scarce literature on the use of different GLP-1RAs in BAD treatment and discuss the potential of different GLP-1RAs in the context of their pharmacokinetic profiles, which we speculate may be important determinants of their mode of actions and, thus, pharmacodynamics in BAD
GLP-1s role in neuroprotection: A systematic review
